R1 RCM has received a noncompliance notice from Nasdaq’s Listing Qualifications Department resulting from R1’s delay in filing its quarterly report on Form 10-Q for the third quarter of 2023. Nasdaq’s ...

In March 2024, R1 RCM Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that an unauthorized party was able to access confidential information belonging ...

MURRAY, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare ...

R1 RCM (NASDAQ:RCM) was downgraded to hold from buy at Deutsche Bank after the shares surged 25% on Monday after New Mountain offered to buy the company for $13.75 a share. Deutsche Bank downgraded ...

New Mountain Capital is offering to buy out other investors in revenue cycle management giant R1 RCM for $13.75 a share in cash. The private equity firm’s offer represents a 24% premium to R1’s ...

MURRAY, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of ...

R1 RCM completed the restatement of previously issued financial statements after it previously identified “errors related to the accounting for certain acquiree compensation costs (e.g., transaction ...

Private equity firms are leading the buyout of R1 RCM, a major provider of billing and administrative services for hospitals and physician groups. But R1’s hospital customers — some of the biggest ...

Fintel reports that on February 28, 2024, Barclays downgraded their outlook for R1 RCM (NasdaqGS:RCM) from Overweight to Equal-Weight. As of February 24, 2024, the average one-year price target for R1 ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -R1 RCM said on Thursday private-equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) would ...

(Reuters) -R1 RCM said on Thursday private-equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) would acquire the healthcare technology company in a deal that values it at $8.9 ...